CRNX
Price
$30.68
Change
+$0.28 (+0.92%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
2.89B
70 days until earnings call
CYTK
Price
$37.34
Change
-$0.49 (-1.30%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
4.47B
63 days until earnings call
Interact to see
Advertisement

CRNX vs CYTK

Header iconCRNX vs CYTK Comparison
Open Charts CRNX vs CYTKBanner chart's image
Crinetics Pharmaceuticals
Price$30.68
Change+$0.28 (+0.92%)
Volume$9.37K
Capitalization2.89B
Cytokinetics
Price$37.34
Change-$0.49 (-1.30%)
Volume$53.37K
Capitalization4.47B
CRNX vs CYTK Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. CYTK commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and CYTK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (CRNX: $30.65 vs. CYTK: $37.35)
Brand notoriety: CRNX and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 90% vs. CYTK: 143%
Market capitalization -- CRNX: $2.89B vs. CYTK: $4.47B
CRNX [@Biotechnology] is valued at $2.89B. CYTK’s [@Biotechnology] market capitalization is $4.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while CYTK’s TA Score has 6 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 4 bearish.
  • CYTK’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а +4.25% price change this week, while CYTK (@Biotechnology) price change was -1.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.10%. For the same industry, the average monthly price growth was +14.72%, and the average quarterly price growth was +30.35%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

CYTK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.47B) has a higher market cap than CRNX($2.89B). CYTK YTD gains are higher at: -20.599 vs. CRNX (-40.055). CRNX has higher annual earnings (EBITDA): -419.62M vs. CYTK (-504.83M). CRNX has more cash in the bank: 1.2B vs. CYTK (858M). CRNX has less debt than CYTK: CRNX (49.9M) vs CYTK (858M). CYTK has higher revenues than CRNX: CYTK (85.7M) vs CRNX (1.39M).
CRNXCYTKCRNX / CYTK
Capitalization2.89B4.47B65%
EBITDA-419.62M-504.83M83%
Gain YTD-40.055-20.599194%
P/E RatioN/AN/A-
Revenue1.39M85.7M2%
Total Cash1.2B858M139%
Total Debt49.9M858M6%
FUNDAMENTALS RATINGS
CRNX vs CYTK: Fundamental Ratings
CRNX
CYTK
OUTLOOK RATING
1..100
872
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
6782
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6258
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (86) in the Pharmaceuticals Major industry is in the same range as CYTK (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to CYTK’s over the last 12 months.

CRNX's Profit vs Risk Rating (67) in the Pharmaceuticals Major industry is in the same range as CYTK (82) in the Biotechnology industry. This means that CRNX’s stock grew similarly to CYTK’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as CYTK (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (58) in the Biotechnology industry is in the same range as CRNX (62) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew similarly to CRNX’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXCYTK
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FNEEX70.970.64
+0.91%
American Funds New Economy 529-F-2
BIAFX44.14N/A
N/A
Brown Advisory Flexible Equity Inv
IRSYX15.71N/A
N/A
Macquarie Real Estate Securities Y
FFEFX15.72N/A
N/A
Nuveen Dividend Value R6
FGILX23.68N/A
N/A
Fidelity Global Equity Income